Quick Facts: Therapeutic Uses

• Relief of discomfort and inflammation associated with musculoskeletal conditions.
• Used in the management of chronic joint conditions.
• Supports improved functional capacity in patients with certain rheumatic disorders.

---

Aceclofenac Ciclum 100 mg is authorized for the symptomatic relief of discomfort and inflammation associated with a range of chronic inflammatory and degenerative joint conditions in adults. Its primary applications focus on the management of long-term conditions that affect the joints and spine, which can result in stiffness and reduced mobility.

The medication is indicated for three main therapeutic domains: osteoarthritis, which involves the degradation of joint cartilage; rheumatoid arthritis, an autoimmune condition causing widespread joint inflammation; and ankylosing spondylitis, which primarily affects the spine and larger joints. In these patient populations, treatment aims to reduce the presence of discomfort and support the maintenance of joint function.

Clinical experience suggests that this medication may offer support in the temporary easing of symptoms, which may contribute to overall functional capacity and well-being. Aceclofenac is generally considered a useful option for managing pain and inflammation across these specific conditions.

Eligibility Map: Who can and cannot use Aceclofenac Ciclum 100 mg Comprimidos

The eligibility for Aceclofenac Ciclum 100 mg, an NSAID, is strictly defined by regulatory authorities based on age, existing medical conditions, and physiological status.

---

Populations for whom use is contraindicated (Must Not Use)

Use is absolutely prohibited for patients with a known hypersensitivity to Aceclofenac, aspirin, or other NSAIDs.

It is also contraindicated in individuals with:

• Severe organ failure (hepatic, renal, or heart failure, NYHA Class II–IV).
• Active or recurrent peptic ulcer/haemorrhage or a history of GI bleeding related to previous NSAID therapy.
• Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
• Active bleeding or bleeding disorders.
• The third trimester of pregnancy.

---

Age and Conditional Eligibility

• Adults are the approved population for this medicine. Use is not recommended in children and adolescents under 18 years of age due to a lack of clinical data.
• Patients with mild to moderate hepatic or renal impairment must only be treated under close medical surveillance.
• The medicine is not recommended for women who are breastfeeding or for those in the first and second trimesters of pregnancy.

Interactions with other medicines and products

The interaction profile of Aceclofenac Ciclum 100 mg Comprimidos is defined by documented pharmacokinetic and pharmacodynamic outcomes, primarily involving increased risk of toxicity or altered drug exposure as stated in official regulatory information.

Interaction Type	Interacting Medicines and Outcomes
Increased Toxicity Risk	Co-administration with other NSAIDs (including high-dose Aspirin) is generally avoided due to a documented increased risk of adverse effects. Anticoagulants (e.g., Warfarin), SSRIs, and Corticosteroids carry an increased risk of bleeding or ulceration. The combination with Ciclosporin or Tacrolimus elevates the risk of nephrotoxicity.
Altered Drug Exposure	Aceclofenac may increase plasma concentrations of Lithium, Digoxin, and Methotrexate by reducing their clearance. Conversely, Aceclofenac may reduce the anti-hypertensive or diuretic effects of co-administered treatments like ACE-inhibitors and Diuretics.

Administration Restrictions and Population Notes

A mandatory time separation is required for certain co-administrations; specifically, use must be restricted for 8 to 12 days following administration of Mifepristone to avoid reduced efficacy. Co-administration with Methotrexate within 24 hours requires careful monitoring. Furthermore, official prescribing information notes that the risk and severity of interaction-related adverse outcomes, particularly acute renal insufficiency, are heightened in the elderly and patients with compromised renal or cardiac function. No official interaction is documented with food, alcohol, or herbal products.

Blocking Prostaglandin Production

Aceclofenac acts as an inhibitor by preferentially targeting the Cyclooxygenase-2 (COX-2) enzyme within cells. This action disrupts the Arachidonic Acid cascade, thereby reducing the synthesis of prostaglandins—key lipid mediators derived from this pathway.

---

Modifying Nociceptive Signal Sensitivity

Lowering the local concentration of sensitizing prostaglandins decreases the excitability of peripheral pain-sensing nerves (nociceptors). This mechanism influences the transmission of neural signals associated with nociception, resulting in altered signaling dynamics within the nociceptive pathway.

---

Readjusting Central Thermoregulatory Signaling

The drug's mechanism affects the central nervous system through a decrease in specific prostaglandins within the hypothalamus. This targeted effect causes a decrease in an elevated thermoregulatory set point, leading to readjustment of core body temperature.

The administration of Aceclofenac Ciclum 100 mg Comprimidos involves specific instructions detailing the route, dosage, frequency, and use pattern.

Administration Scope

Feature	Official Labeled Instruction
Route of administration	Oral use
Standard Dosing Schedule (Adults)	200 mg daily taken as two separate 100 mg doses
Maximum Recommended Dose	200 mg daily
Timing in relation to meals	To be taken preferably with or after food
Age-group administration rules	Pediatric: Not recommended for use in children. Hepatic Impairment: Initial dose is suggested to be 100 mg daily.

Official Administration Guidelines

Aceclofenac 100 mg tablets are supplied for oral administration and are to be swallowed whole with a sufficient quantity of liquid; they are not to be crushed or chewed. The adult regimen consists of two 100 mg tablets per day, typically taken as one tablet in the morning and one in the evening.

The overall use protocol requires employing the lowest effective dose for the shortest duration necessary to control symptoms. If a dose is missed, patients are generally advised not to take a double dose but to continue with the next scheduled dose at the usual time.

Research Evidence / Overview of Studies for Aceclofenac Ciclum 100 mg Comprimidos

This overview summarizes the formal research studies and clinical trial findings that governmental and intergovernmental bodies rely on when evaluating this medicine. It focuses on the research structure and reported observations, not on individual advice or treatment decisions.

---

Evidence for Use in Osteoarthritis (OA)

Research exploring how symptoms change over time in osteoarthritis (OA) has relied mainly on Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms of OA in adult patients. Researchers examined outcomes related to physical discomfort, such as measurements of pain intensity and detailed evaluations of daily functioning or activity level. Findings describe patterns observed in the studies, where changes in pain scores and functional capacity were measured over the observation periods. Synthesized evidence from some reviews reported that the measurements for pain and function were generally recorded alongside established non-steroidal anti-inflammatory comparators. The research so far indicates that results apply only to the populations studied.

---

Evidence for Use in Rheumatoid Arthritis (RA)

Research on rheumatoid arthritis (RA) was evaluated in studies focusing on episodes where symptoms become more noticeable. These primarily involved RCTs comparing the medicine against other treatments used for RA. Study outcomes examined in adult patients included outcomes linked to inflammatory states, such as counts of swollen or tender joints, and measurements of the duration of morning stiffness. Regulatory documentation reported that the observed measurements for symptoms appeared consistent with those recorded in the groups receiving comparator drugs. The research exploring short-term symptom changes in RA generally utilized trials with an observation period of up to three months.

---

What is Still Uncertain About Aceclofenac Ciclum 100 mg Comprimidos

While research has explored how symptoms change over time, certainty remains low regarding several aspects of its use in a real-world setting. Key research limitation frames include:

• Limited Long-Term Data: Follow-up durations were limited, with most trials running for only 4 to 12 weeks. There is limited information for long-term outcomes, as existing studies provide limited insight into the maintenance of symptomatic changes.
• Small Sample Sizes and Variability: Evidence quality varies across studies, and some comparative research in indications like ankylosing spondylitis often utilized small sample sizes.
• Comparative Evidence Gaps: Comparative evidence is lacking against the full range of newer NSAIDs that may be available in the clinical setting today.

Findings describe group patterns observed in the specific conditions under which they were conducted. This research contributes to the documentation of what has been observed so far.

Common questions about Aceclofenac Ciclum 100 mg Comprimidos (FAQ)

Q: How quickly does Aceclofenac Ciclum usually start working?

Official product information, based on pharmacokinetic data, indicates how quickly the active substance is absorbed. Peak plasma concentrations (when the amount of medicine in the blood is highest) are typically reached approximately 1.25 to 3.00 hours following oral ingestion of the tablet. This measurement provides an indication of the active substance becoming available in the body for its intended effect.

Q: How long can the effects of Aceclofenac Ciclum 100 mg last after taking it?

The duration of the substance in the body is described by its mean plasma elimination half-life. This measure, which indicates the time it takes for half of the drug to be eliminated from the bloodstream, is around 4 hours for Aceclofenac. This half-life value is used by regulatory bodies to characterize the drug's overall action profile.

Q: Can Aceclofenac Ciclum cause changes in mood or anxiety levels?

Regulatory documents list a few psychiatric effects among the possible adverse events. Though generally rare or very rare, these reported effects can include somnolence (sleepiness), insomnia, depression, and abnormal dreaming. For any concerns regarding mental well-being while taking this medicine, consulting with a healthcare professional is recommended.

Q: If I have mild asthma, is it still possible to use Aceclofenac Ciclum?

According to official safety warnings, Aceclofenac is contraindicated (must not be used) in people who have previously experienced asthma attacks or severe rhinitis (nasal inflammation) after taking aspirin or other NSAIDs. Official documentation specifies that patients with a history of asthma or other breathing-related disorders should be managed with caution.

Q: How is Aceclofenac Ciclum eliminated from the body?

The elimination of the active substance, Aceclofenac, follows a defined metabolic pathway. Approximately two-thirds of the administered dose is excreted primarily via the urine, most of which is in the form of its metabolic breakdown products (hydroxymetabolites). The remaining amount is generally excreted in the faeces.

Q: Can I drive or operate machinery after taking Aceclofenac Ciclum?

Official safety warnings state that if a patient experiences dizziness, vertigo, drowsiness, or other disturbances affecting the central nervous system, official safety documents indicate the need to refrain from driving or operating machinery in these circumstances. This warning is included because the medicine may affect these functions in certain individuals.

Q: Can taking Aceclofenac Ciclum cause fluid retention or swelling?

Yes, fluid retention and edema (swelling) have been reported in association with the use of NSAID medicines, the class to which Aceclofenac belongs. Due to this possibility, official documents specify that patients with a history of hypertension (high blood pressure) or mild to moderate heart failure require safety monitoring.

Q: Can sunlight exposure be an issue while taking Aceclofenac Ciclum?

While not listed as a common reaction, photosensitivity reaction is a reported class effect linked to NSAIDs. Photosensitivity means increased skin sensitivity to light, often sunlight. This rare possibility is noted in official documentation.

How to Store and Dispose of Aceclofenac Ciclum 100 mg Tablets

The storage and handling of Aceclofenac tablets are governed by official regulatory requirements to ensure product stability.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C. Some regulatory labels specify storage below 25 C.
Protection	The product must be protected from light.
Child Safety	Keep out of the sight and reach of children.

The tablets are typically supplied in their original aluminium blister packaging. Beyond temperature and light control, no other special storage conditions are generally required.

Disposal Instructions

Any unused or expired Aceclofenac product and associated waste material must be disposed of in strict accordance with local regulatory requirements and established guidelines for medicinal waste.